Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.

Abstract: The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 expression or PAI-1 activity. Another embodiment of the present invention is a method of treating a PAI-1-associated ocular disorder in a subject in need, comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 activity or expression.

Abstract: 1,4-disubstituted-1,2,3-triazole UV absorbing monomers are disclosed. The UV absorbers are particularly suitable for use in intraocular lens materials.

Abstract: The invention provides genes and polymorphisms associated with AMD, and methods for diagnosing an increased risk of AMD in a patient who has at least one of the AMD-associated polymorphisms as provided.

Abstract: A method and apparatus to operate a surgical instrument in response to a thermal condition being detected that warrants curtailment of further operation. When the thermal condition is reached, command signals are generated that cause a needle of the surgical instrument to either have its vibrational speed slowed, have its vibrational movement stopped, or have it withdrawn from its relative position. The detection is of infrared radiation wavelengths and is carried out with either a thermal imaging device of a thermal recognition device. A corresponding temperature of the detected infrared radiation wavelengths is compared to a critical temperature to determine whether the thermal condition has been reached.

Abstract: Methods for preventing and treating damage to the optic nerve and/or retina by the use of SOD mimics, particularly pentaazacycle Mn(II) complex SOD mimics, are disclosed.

Abstract: A system and method for aligning a first and a second image of an eye includes making a determination of a limbus location on a first eye image and a second eye image. The limbus location of the first and the second eye images are then aligned in two dimensions. A second eye feature location is determined on the first and the second eye image. One of the first and the second eye image is relatively rotated, and a correlation is performed on the first and the second eye image at a plurality of relative rotational positions using the second eye feature location. From the correlation an optimal first and second image alignment is identified.

Abstract: A system and method for identifying a component for use with a surgical device are disclosed. A component of a surgical device includes an identifier, such as a RFID tag. Data from the RFID tag is transmitted to a RFID reader operably coupled to the device. A controller identifies the component based on the received data and determines whether the component can be used with the surgical device based on criteria, such as whether the received data is an authorized code that matches data stored in memory or whether the received data solves or satisfies an algorithm. The authorized codes are selected from a larger set of available codes. The controller can enable or disable the operation of the device with the component based on whether the criteria is satisfied and can cause the surgical device to be configured for use with the component.

Abstract: The use of HMG-CoA reductase inhibitors (e.g., statins) to treat glaucoma, control intraocular pressure, preserve the trabecular meshwork, protect against ocular neurodegeneration and/or protect against glaucomatous retinopathy is described. The preferred HMG-CoA reductase inhibitors, which are statins having an RI value of 0.2 to 0.7 (e.g., pravastatin), are administered via topical application to the affected eye(s) of the patient.

Abstract: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).

Abstract: The topical use of 5,6,7-trihydroxyheptanoic acid and analogs are disclosed for the treatment of dry eye disorders and uveitis.

Abstract: The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.

Abstract: Compositions containing 5,6,7-trihydroxyheptanoic acid and analogs and their use for treating posterior segment ocular diseases and diseases characterized by cellular hyperproliferation or angiogenesis, are disclosed.

Abstract: The invention provides solution compositions comprising olopatadine and a PDE4 inhibitor compound of Formula I: The invention also provides methods for treating allergic and inflammatory diseases. More particularly, the present invention relates to formulations of olopatadine and their use for treating and/or preventing allergic or inflammatory disorders of the eye, nose, skin, and ear.

Abstract: Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.

Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.

Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.

Abstract: A glaucoma drainage device has a tube shunting the anterior chamber to a drainage location. A power generator has a rotor coupled to a micro-generator. The power generator is configured to generate energy from aqueous flowing through the tube. The force required to drive the rotor can be controlled to control the flow of aqueous through the tube. Alternatively, energy generated by the power generator is stored in a power source that powers an active valve, a pressure sensor, or telemetry.

Abstract: The present invention relates to a formulation comprising a N-halogenated amino acid and a phase transfer agent. The present invention also describes a method for disinfecting and/or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid salt for a time sufficient to disinfect and/or clean the lens.

Abstract: A glaucoma drainage device may comprise a main drainage tube with a first end configured to be located in an anterior chamber of an eye and a second end configured to be located in a drainage location. A bypass drainage tube is fluidly coupled to and in parallel with the main drainage tube. A pump is in communication with the bypass drainage tube. The pump comprises a first driver and a first flexible membrane enclosing a first chamber. A first check valve is located upstream of the pump, and a second check valve is located downstream of the pump. An active valve is located upstream of the first check valve. The active valve comprises a second driver and a second flexible membrane enclosing a second chamber. A third check valve is located between the active valve and the second end of the main drainage tube. A volume of the first chamber is changed to pump fluid from the anterior chamber to the drainage location.